Seres Therapeutics (MCRB) Projected to Post Earnings on Thursday

Seres Therapeutics (NASDAQ:MCRB) is anticipated to release its Status update results before the market opens on Thursday, March 12th. Analysts expect Seres Therapeutics to post earnings of ($2.39) per share for the quarter. Interested persons may review the information on the company’s upcoming Status update earning report for the latest details on the call scheduled for Tuesday, March 3, 2026 at 8:30 AM ET.

Seres Therapeutics Stock Up 3.8%

Shares of MCRB opened at $9.13 on Thursday. Seres Therapeutics has a twelve month low of $6.53 and a twelve month high of $29.98. The company has a market capitalization of $82.63 million, a P/E ratio of -2.56 and a beta of 0.31. The firm has a 50 day moving average of $13.15 and a 200 day moving average of $16.23.

Institutional Investors Weigh In On Seres Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Invesco Ltd. boosted its stake in shares of Seres Therapeutics by 193.2% in the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 89,995 shares during the period. Goldman Sachs Group Inc. boosted its stake in Seres Therapeutics by 40.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 21,679 shares during the period. Marshall Wace LLP bought a new position in Seres Therapeutics in the 2nd quarter worth approximately $1,016,000. Vanguard Group Inc. grew its holdings in Seres Therapeutics by 6.8% during the 3rd quarter. Vanguard Group Inc. now owns 311,889 shares of the biotechnology company’s stock valued at $6,001,000 after buying an additional 19,793 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC bought a new stake in shares of Seres Therapeutics during the third quarter valued at approximately $557,000. 59.34% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

MCRB has been the subject of a number of research analyst reports. Wall Street Zen lowered Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Weiss Ratings reiterated a “sell (d)” rating on shares of Seres Therapeutics in a report on Monday, December 29th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus price target of $14.33.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.